[Monitoring of chimerism in myeloid cells sorting of transplanted patients with acute myeloid leukaemia: a study from Lyon (France)].
Chimerism analysis after allogeneic haematopoietic stem cell transplantation has been used to document engraftment and to adapt therapy promptly. The aim of this study was to document engraftment and to detect as soon as possible relapse in patients with acute myeloid leukaemia who underwent stem cell transplantation. Real-time quantitative polymerase chain reaction is a highly sensitive and reproducible technology. It is useful in some disease to target selected sub-populations in order to have an earlier detection of relapse on cell fractions. In the acute myeloid leukaemia (n=65), analysis of the chimerism on whole peripheral blood cells and bone marrow cells, CD3+ cells, specific myeloid CD33+ cells (from blood) and CD34+ cells (from bone marrow) is of importance. After transplant, 25 patients relapsed (38%), three massively, with chimerism detection in whole blood and bone marrow and 22 insidiously following two different schemes (GRI and GRII). In GRI, (n=13): chimerism of CD33+ and CD34+ cellular fractions allowed an early detection of relapse in 100% of cases undetected in whole cells whereas in GRII (n=9): myeloid cells could identified relapse in 89% of cases when whole blood cells and CD3+ cells expressed a mixed chimerism. This study highlighted the importance of sub-cellular population chimerism documentation enable to ascertain a stable engraftment and to detect early relapse. The selection of sub-cellular population studied with high sensitive technology allows a rapid and efficient intervention before the onset of clinical signs in patient with acute myeloid leukaemia and could improve the patient's follow-up.
Mollet
I
I
Laboratoire d'histocompatibilité, Établissement français du sang, Rhône Alpes site de Lyon, Lyon, France. isabelle.mollet@efs.sante.fr
Giannoli
C
C
Rigal
D
D
Michallet
M
M
Dubois
V
V
D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000502:physiology*; D046528:Chimerism; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D022423:Myeloid Cells / Q000166:cytology* / Q000276:immunology; D018183:Transplantation Chimera / Q000502:physiology; D014184:Transplantation, Homologous; D055815:Young Adult